SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (“CMS”) has notified Merit that its application for Transitional Pass-Through (“TPT”) incremental payment for WRAPSODY ® Cell-Impermeable Endoprosthesis (“CIE”) procedures in the outpatient and ambulatory surgery... Read More

The target lesion primary patency (TLPP) 1 and access circuit primary patency (ACPP) 2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 months The clinical improvements associated with the WRAPSODY CIE are projected to improve the interventional landscape for hemodialysis patients who experience venous outflow obstructions SOUTH JORDAN, Utah,... Read More

At 24 months, the target lesion primary patency (TLPP) 1 was 41.7% At 24 months, the access circuit primary patency (ACPP) 2 was 25.7% SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the... Read More

Highlights† Reported revenue of $384.2 million, up 13.0% Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectively GAAP operating margin of 11.1%, compared to 11.0% in prior year period Non-GAAP operating margin* of 19.7%, compared to 19.2% in prior year period GAAP EPS $0.46, down 3.0% Non-GAAP EPS* $0.92, up 6.7% Free cash flow* generation of $141.6 million over first nine months... Read More

Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders. Asset acquisition is projected to add approximately $6 million to $8 million of revenue in 2026 in a key gastroenterology market that leverages Merit’s existing commercial footprint. SOUTH JORDAN, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Merit Medical... Read More

SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2025, after the close of the stock market on Thursday, October 30, 2025. Merit plans to hold its investor conference call on the same day (Thursday, October 30, 2025)... Read More

SCOUT Radar Localization use grows, supporting more successful surgeries and improved patient care SOUTH JORDAN, Utah, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced a significant milestone for breast cancer treatment: SCOUT® Radar Localization use has reached 750,000 patients worldwide. 1 This global achievement coincides with Breast... Read More

Expanded indication provides patients with knee osteoarthritis the benefits of Embosphere’s consistent, predictable, and effective clinical results. SOUTH JORDAN, Utah, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that Embosphere ® Microspheres are now indicated in the European Union for use in genicular artery embolisation (GAE) to... Read More

The WRAP North America registry is a prospective, multicenter study designed to collect real-world safety and effectiveness data on the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE). The first WRAP North America patient was enrolled at Bluff City Vascular, an interventional nephrology and vascular access center in Memphis, TN. SOUTH JORDAN, Utah, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI),... Read More

Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access procedures and may aid in reducing arterial spasm and occlusion SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™... Read More

Highlights† Reported revenue of $382.5 million, up 13.2% Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectively GAAP operating margin of 12.3%, compared to 13.6% in prior year period Non-GAAP operating margin* of 21.2%, compared to 20.1% in prior year period GAAP EPS $0.54, down 11.6% Non-GAAP EPS* $1.01, up 9.8% Free cash flow* generation of $89.1 million over first six months... Read More

Fred Lampropoulos will continue to serve as Chairman of Merit’s Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today the appointment of Martha Aronson as Merit’s new President and Chief Executive Officer, effective October... Read More

SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00... Read More

Acquired business offers the StatSeal ® and WoundSeal ® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile Merit reaffirms full-year 2025 financial guidance... Read More

The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients. Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc . (NASDAQ: MMSI), a global leader of healthcare technology, announced today... Read More

SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium held in London, England, on April 23, 2025, during the Vascular Access Masterclass session. Following the scientific podium presentation, results were... Read More

First Quarter Highlights† Reported revenue of $355.4 million, up 9.8% Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectively GAAP operating margin of 11.5%, compared to 11.1% in prior year period Non-GAAP operating margin* of 19.3%, compared to 17.0% in prior year period GAAP EPS $0.49, up 2.0% Non-GAAP EPS* $0.86, up 14.8% Free cash flow* generation of $19.5 million, down 20.5%... Read More

SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of solutions to improve cardiac... Read More

SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (Thursday, April 24, 2025) at... Read More

SOUTH JORDAN, Utah, March 27, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the American Society for Gastrointestinal Endoscopy (ASGE) updated its guideline on the diagnosis and management of gastroesophageal reflux disease (GERD) to include Transoral Incisionless Fundoplication (TIF 2.0) and TIF 2.0 Consecutive Transoral Incisionless... Read More

At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively. At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target lesion primary patency and access circuit primary patency, respectively. SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced... Read More

SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on Wednesday, March 19, 2025. The ceremony begins at 9:15 A.M. (EDT) and the bell ringing takes place at 9:30 A.M. "Merit’s listing on Nasdaq... Read More

SOUTH JORDAN, Utah, March 10, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in premature infants (PREEMIE study). PDA is a congenital heart condition that occurs when the ductus arteriosus,... Read More

Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4% Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectively GAAP operating margin of 10.3%, compared to 10.4% in prior year period Non-GAAP operating margin* of 19.6%, compared to 16.6% in prior year period GAAP EPS $0.46, down 2.6%, Non-GAAP EPS* $0.93, up 25.8%, and Free cash flow* generation of $65.3 million,... Read More

2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year 2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year 2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial... Read More

Unique cell-impermeable 1 design extends life-saving treatment for dialysis patients Merit to host a WRAPSODY informational call on January 28, 2025 SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY ® Cell-Impermeable Endoprosthesis has received premarket approval from the US... Read More

SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI) (“Merit” or the “Company”), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright’s resignation, Merit had received notice of allegations regarding his conduct, which Merit’s independent directors... Read More

SOUTH JORDAN, Utah, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced positive six-month findings from the single-arm AVG cohort of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial. The data were presented at the 51 st annual VEITHsymposium during the Novel Technologies in Hemodialysis Access session. An AVG is a synthetic... Read More

SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical’s lead management portfolio. The purchase consideration consisted of a cash payment of approximately $210 million and the assumption of certain liabilities. Merit funded the acquisition payment through a combination of... Read More

Third Quarter 2024 Highlights† Reported revenue of $339.8 million, up 7.8% Constant currency revenue* and constant currency revenue, organic* up 7.9% and up 5.7%, respectively GAAP operating margin of 11.0%, compared to 11.1% in prior year period Non-GAAP operating margin* of 19.2%, compared to 17.4% in prior year period GAAP EPS $0.48, up 8.0%, and non-GAAP EPS* $0.86, up 21.1% Generated free cash flow* $120 million over... Read More

SOUTH JORDAN, Utah, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2024, after the close of the stock market on Wednesday, October 30, 2024. Merit will hold its investor conference call on the same day (Wednesday, October 30, 2024)... Read More

Asset acquisition of Cook Medical’s end-to-end lead management product portfolio strengthens Merit’s existing electrophysiology and CRM business Asset acquisition projected to add approximately $40 million of revenue, on an annualized basis beginning in fiscal year 2025, with a solid growth profile serving an underpenetrated global lead management market Merit reaffirms full-year 2024 financial guidance previously issued on... Read More

SOUTH JORDAN, Utah, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced positive 6-month findings from the randomized arteriovenous (AV) fistula arm of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial. The data were shown at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) during a FIRST@CIRSE... Read More

SOUTH JORDAN, Utah, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that clinicians will present updates on two of its pivotal studies during scientific sessions held on September 14 at CIRSE in Lisbon, Portugal. Data will include 6-month clinical outcomes from the WAVE study, presented during the FIRST@CIRSE... Read More

Second Quarter 2024 Highlights† Reported revenue of $338.0 million, up 5.6% Constant currency revenue* up 6.6% Constant currency revenue, organic,* up 5.0% GAAP operating margin of 13.6%, compared to 9.0% in prior year period Non-GAAP operating margin* of 20.1%, compared to 19.1% in prior year period GAAP EPS $0.61, up 75.7% Non-GAAP EPS* $0.92, up 16.8% † Comparisons noted in the bullet points are calculated for the current... Read More

SOUTH JORDAN, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced plans to release findings from its WAVE study. A pivotal, international, multicenter trial, the WAVE study examines the safety and efficacy of Merit’s WRAPSODY Cell-Impermeable Endoprosthesis for treatment of stenosis in the venous outflow circuit. The WAVE study enrolled... Read More

Asset acquisition expands Merit’s endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD). Asset acquisition projected to add approximately $30 million of revenue, on an annualized basis, in key gastrointestinal endoscopy market that leverages existing commercial footprint. Merit reaffirms full-year 2024 financial guidance on standalone basis and... Read More

SOUTH JORDAN, Utah, June 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2024, after the close of the stock market on Thursday, August 1, 2024. Merit will hold its investor conference call on the same day (Thursday, August 1, 2024) at 5:00 p.m.... Read More

SOUTH JORDAN, Utah, May 21, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the basixSKY Inflation Device. BasixSKY is the latest addition to Merit’s comprehensive inflation device portfolio, which includes both digital and analog devices. The basixSKY is available as a standalone solution and in kits with Merit... Read More

SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc . (NASDAQ: MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit’s Annual Meeting of Shareholders held on May 15, 2024. Merit’s shareholders also re-elected Fred P. Lampropoulos and... Read More

Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports “Continued Growth Initiatives” Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit’s global... Read More

New products broaden Merit’s leadership in embolotherapy. Full portfolio will be exhibited at the 18 th Annual GEST Meeting May 16-19 in New York City. SOUTH JORDAN, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced US Food and Drug Administration (FDA) 510(k) clearance for its Siege Vascular Plug. Merit also announced the launch of... Read More

Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023 Q1 2024 constant currency revenue* up 9.3% compared to Q1 2023 Q1 2024 constant currency revenue, organic* up 7.0% compared to Q1 2023 Q1 2024 GAAP operating margin of 11.1%, compared to 8.9% in Q1 2023 Q1 2024 non-GAAP operating margin* of 17.3%, compared to 16.1% in Q1 2023 Q1 2024 GAAP EPS $0.48, up 35.5%, compared to $0.36 in Q1 2023 Q1 2024 non-GAAP... Read More

SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System. Merit also intends to file Micro ACE for CE mark designation. The Micro ACE system is the latest innovation in the Merit Vascular portfolio. The comprehensive... Read More

SOUTH JORDAN, Utah, March 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2024, after the close of the stock market on Tuesday, April 30, 2024. Merit will hold its investor conference call on the same day (Tuesday, April 30, 2024) at 5:00 p.m.... Read More

SOUTH JORDAN, Utah, March 05, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today a series of events for clinicians attending the 2024 SIR Annual Meeting. These educational events will take place at Merit’s headquarters and at SIR booth 320. On March 26, Merit will host an Evening of Innovation at its Salt Lake City headquarters from 6:30 p.m.– 9:00... Read More

Q4 2023 reported revenue of $324.5 million, up 10.6% year-over-year Q4 2023 constant currency revenue* up 10.3% year-over-year Q4 2023 constant currency revenue, organic* up 8.3% year-over-year Q4 2023 GAAP operating margin of 10.4%, compared to 10.4% in Q4 2022 Q4 2023 non-GAAP operating margin* of 18.2%, compared to 17.8% in Q4 2022 Q4 2023 GAAP EPS $0.47, compared to $0.58 in Q4 2022 Q4 2023 non-GAAP EPS* $0.81, compared... Read More

SOUTH JORDAN, Utah, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today introduced its Continued Growth Initiatives Program and related financial targets for the three-year period ending December 31, 2026. Merit’s new multi-year financial targets are: Total revenue increase at a compound annual growth rate (CAGR) of 5% to 7%... Read More

SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. ( NASDAQ: MMSI), a global leader of healthcare technology, has received US Food and Drug Administration (FDA) 501(k) clearance for the SCOUT ® MD™ Surgical Guidance System. The release of the new guidance system demonstrates Merit’s ongoing leadership in oncology and marks a significant advancement in breast cancer care. SCOUT MD broadens... Read More

SOUTH JORDAN, Utah, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the successful enrollment of the first patient in its multicenter, prospective, randomized, controlled trial comparing genicular artery embolization (GAE) using Embosphere® Microspheres to corticosteroid injections for the treatment of... Read More

2023 reported preliminary unaudited revenue in the range of approximately $1.255 billion - $1.259 billion, up approximately 9.0% - 9.4% year-over-year 2023 preliminary unaudited constant currency revenue* in the range of up approximately 9.6% - 9.9% year over year 2023 financial results and 2024 guidance to be released February 28, 2024 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this... Read More

SOUTH JORDAN, Utah, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that Merit Chairman and CEO, Fred Lampropoulos, is scheduled to present at the J.P. Morgan 42 nd Annual Healthcare Conference on January 8, 2024, at 4:30pm PT. A live audio webcast of the conference presentation will be available on the investor... Read More

SOUTH JORDAN, Utah, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today outlined the ongoing succession planning process for its Chief Executive Officer (CEO). Pursuant to an Amended and Restated Employment Agreement, effective June 8, 2023, Merit founder, CEO, and President, Fred Lampropoulos, will continue to serve as... Read More

SOUTH JORDAN, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced the pricing of $650.0 million aggregate principal amount of 3.00% Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) only to persons reasonably believed to be “qualified institutional buyers” pursuant to... Read More

SOUTH JORDAN, Utah, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced today that it intends to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) only to persons reasonably... Read More

Q3 2023 reported revenue of $315.2 million, up 9.8% year-over-year Q3 2023 constant currency revenue* up 9.7% year over year Q3 2023 constant currency revenue, organic* up 7.1% year-over-year Q3 2023 GAAP operating margin of 11.1%, compared to 6.5% in Q3 2022 Q3 2023 non-GAAP operating margin* of 18.3%, compared to 16.1% in Q3 2022 Q3 2023 GAAP EPS $0.44, compared to $0.27 in Q3 2022 Q3 2023 non-GAAP EPS* of $0.75, compared... Read More

SOUTH JORDAN, Utah, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the expansion of its Maestro Microcatheter product line to now include a new longer length for radial embolization procedures. The Maestro is part of a comprehensive offering of embolotherapy solutions, which includes Embosphere® Microspheres,... Read More

SOUTH JORDAN, Utah, Oct. 05, 2023 (GLOBE NEWSWIRE) - - Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2023, after the close of the stock market on Thursday, October 26, 2023. Merit will hold its investor conference call on the same day (Thursday, October 26, 2023) at... Read More

SOUTH JORDAN, Utah, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc . (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of its Aspira Bottle. The new evacuated drainage bottle is the latest addition to Merit’s drainage portfolio. Offering a wide range of intervention products, solutions, and accessories, the comprehensive portfolio... Read More

SOUTH JORDAN, Utah, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit’s WAVE study is a prospective, randomized, controlled, multicenter study comparing the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) to... Read More

Q2 2023 reported revenue of $320.1 million, up 8.5% year-over-year Q2 2023 constant currency revenue* up 9.4% year over year Q2 2023 constant currency revenue, organic* up 9.1% year-over-year Q2 2023 GAAP operating margin of 9.0%, compared to 7.9% in Q2 2022 Q2 2023 non-GAAP operating margin* of 19.9%, compared to 19.1% in Q2 2022 Q2 2023 GAAP EPS $0.35, compared to $0.27 in Q2 2022 Q2 2023 non-GAAP EPS* of $0.81, compared... Read More

SOUTH JORDAN, Utah, July 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2023, after the close of the stock market on Tuesday, July 25, 2023. Merit will hold its investor conference call on the same day (Tuesday, July 25, 2023) at 5:00 p.m.... Read More

Acquisitions broaden Merit’s therapeutic platform with diverse dialysis product solutions and expand its access catheter offering Acquisitions projected to add approximately $30 million of revenue, on an annualized basis, in key strategic markets that leverage existing commercial footprint Merit re-affirms full-year 2023 financial guidance on stand-alone basis and updates full-year 2023 financial guidance to include... Read More

SOUTH JORDAN, Utah, June 07, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that it has entered into a new, five-year senior secured credit agreement. The credit agreement includes a revolving credit facility in an aggregate principal amount of up to $700 million and a term loan facility in an aggregate principal amount... Read More

Q1 2023 reported revenue of $297.6 million, up 8.0% compared to Q1 2022 Q1 2023 constant currency revenue, organic* up 9.8% compared to Q1 2022 Q1 2023 GAAP operating margin of 8.9%, compared to 5.5% in Q1 2022 Q1 2023 non-GAAP operating margin* of 16.1%, compared to 14.6% in Q1 2022 Q1 2023 GAAP EPS $0.36, compared to $0.18 in Q1 2022 Q1 2023 non-GAAP EPS* of $0.64, compared to $0.53 in Q1 2022 * Constant currency revenue;... Read More

SOUTH JORDAN, Utah, April 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2023, after the close of the stock market on Wednesday, April 26, 2023. Merit will hold its investor conference call on the same day (Wednesday, April 26, 2023) at 5:00... Read More

SOUTH JORDAN, Utah, March 20, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the expansion of its SwiftNINJA Steerable Microcatheter product line. New sizes include a low-profile 2.4F distal diameter option in 125-cm and new longer 150-cm lengths. The 180-degree articulating microcatheter is designed to provide access... Read More

Q4 2022 reported revenue of $293.4 million, up 5.4% compared to Q4 2021 Q4 2022 constant currency revenue, organic* up 8.2% compared to Q4 2021 Q4 2022 GAAP operating margin of 10.4%, compared to 7.9% in Q4 2021 Q4 2022 non-GAAP operating margin* of 17.8%, compared to 17.4% in Q4 2021 Q4 2022 GAAP EPS $0.58, compared to $0.36 in Q4 2021 Q4 2022 non-GAAP EPS* of $0.79, compared to $0.71 in Q4 2021 * Constant currency revenue;... Read More

SOUTH JORDAN, Utah, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today the FDA has granted Breakthrough Device Designation for the SCOUT MD Surgical Guidance System. The SCOUT MD is the latest step in Merit’s ongoing commitment and leadership in advancing oncology care. SCOUT MD expands Merit’s portfolio of... Read More

SOUTH JORDAN, Utah, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the fourth quarter and year ended December 31, 2022, and issue fiscal year 2023 guidance after the close of the stock market on Wednesday, February 22, 2023. Merit will hold its investor conference... Read More

SOUTH JORDAN, Utah, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today the successful enrollment of the first patient in its prospective, observational study of EmboCube Embolization Gelatin used to control bleeding or hemorrhage. Uncontrolled bleeding, particularly as a result of trauma, is a leading cause of... Read More